Publication details

Renální karcinom a imunoterapie

Title in English Renal carcinoma and immunotherapy


Year of publication 2016
Type Article in Periodical
Magazine / Source Onkologie
MU Faculty or unit

Faculty of Medicine

Field Oncology and hematology
Keywords renal carcinoma; immunotherapy; checkpoint inhibitors; vaccines
Description Although immunotherapy in patients with metastatic renal cancer is experiencing an unprecedented renaissance, the disease still remains incurable. The use of various checkpoint inhibitors and anti-tumour vaccines, however, leads to further prolongation of survival of patients with this condition. The results of phase III trials with the anti-PD-1 antibody nivolumab are already available, with the next ones being eagerly anticipated. Moreover, enrolment has been completed for the phase III ADAPT trial in which a targeted therapy is combined with an anti-tumour vaccine; the results of the phase II trial with this therapy are very promising. The present review deals with both checkpoint inhibitors and some vaccines. Due to their marginal importance nowadays, treatment with cytokines is dealt with only briefly even though their use in combination with the existing treatment or at high doses in various genotypes of renal cancer cannot be excluded in the future.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.

More info